Daniel B. Soland - Apr 1, 2022 Form 4 Insider Report for IDERA PHARMACEUTICALS, INC. (IDRA)

Role
CHIEF OPERATING OFFICER
Signature
/s/ Daniel B. Soland
Stock symbol
IDRA
Transactions as of
Apr 1, 2022
Transactions value $
$0
Form type
4
Date filed
4/4/2022, 05:43 PM
Previous filing
Jan 26, 2022
Next filing
Jun 9, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IDRA Stock Option (Right to Buy) Award $0 +41.5K $0.00 41.5K Apr 1, 2022 Common Stock 41.5K $0.54 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option will vest and become exercisable in full on January 24, 2026, with 25% vesting on January 24, 2023, and the remainder vesting in twelve equal quarterly installments over the remaining three years, subject to continued service with the Issuer.